Skip to main content
. 2015 Sep 21;1(1):e00013. doi: 10.1016/j.heliyon.2015.e00013

Fig. 3.

Fig. 3

Id2 upregulation by donepezil-dependent inhibition of osteoclast differentiation and donepezil does not induce apoptosis in osteoclast. A, The expression of Id2 mRNA in BMMs with donepezil (0, 0.5 and 5 μg/ml) in the presence of RANKL for 24 h estimated by qPCR analysis. Data are calculated from three repeated experiments. B, The expression of Id2 and c-Fos protein in BMMs with donepezil (0, 0.5 and 5 μg/ml) in the presence of RANKL for 36 h estimated by Western blot analysis. Data are calculated from three repeated experiments. C, Expression of RANK mRNA in BMMs with donepezil (5 mg/ml) for the indicated times estimated by qPCR analysis. Data are calculated from three repeated experiments. D, Detection of apoptotic cells in BMMs stimulated by donepezil (5 μg/ml) or carbamylcholine (CCh at 1 μM) in the presence of RANKL for 48 h. Data are calculated from three repeated experiments. RANKL, receptor activator of nuclear factor-κB ligand; BMMs, bone marrow macrophages; TRAP, tartrate-resistant acid phosphatase; Id2, inhibitors of differentiation/DNA binding 2; #, p < 0.05. Data are expressed as the means ± S.D.